Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating lisocabtagene maraleucel (JCAR017) in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell Non-Hod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)

Snippet

Sponsor: Celgene | Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-15